Low pass whole methylome enzymatic sequencing of four AML cell lines untreated and after treatment with different concentrations of 5-azacytidine (AZA), 5-aza-2′-deoxycytidine (DEC), Cytarabine (ARAC) and GSK3685032 (GSK5032) for 3 and 7 days